Report published by the OHE examines EU authorised products and the appraisal recommendations they subsequently received in the UK
A consulting report, titled ‘Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure‘, has been published by the Office of Health Economics (OHE). The report examines products that have been granted a marketing authorisation via the centralised procedure of the European Medicines Agency (EMA) and the health technology appraisal (HTA) recommendations they subsequently received.
Publicly available appraisal information was gathered and analysed from National Institute for Health and Care Excellence (NICE), NHS England, All Wales Medicines Strategy Group (AWMSG) and the Scottish Medicines Consortium (SMC).
The selection criteria for the study was centrally authorised products which received an initial authorisation (or an extension to the initial indication) between 1 January 2011 and 31 December 2016 across England, Scotland and Wales, with a focus on orphan and oncology medicinal products.
The study reports that “a substantial number of products which received an EU authorisation between 2011 and 2016 were not evaluated by the HTA bodies in Great Britain” and that oncology and orphan products were “associated with a lower odds of receiving a positive HTA recommendation” compared with non-oncology and non-orphan products.